An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

As Australia’s obsession with tanning rages on, people are turning to nasal sprays as a ‘safer’ way to tan. Experts say there ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.